11:20 AM EDT, 06/16/2025 (MT Newswires) -- Phathom Pharmaceuticals ( PHAT ) said Monday that the US Food and Drug Administration has corrected its approved drug products with therapeutic equivalence evaluations, or Orange Book, to accurately reflect the 10-year new chemical entity exclusivity period for Voquezna tablets to treat heartburn.

The updated listing confirms regulatory exclusivity for Voquezna through May 3, 2032, the company said.

Shares of Phathom Pharmaceuticals ( PHAT ) were down 6% in recent trading.

Price: 10.00, Change: -0.64, Percent Change: -6.02